Rheumatic Complications of Cancer Immunotherapy: A New and Emerging Field in Rheumatology is organized by Vindico Medical Education.

Release Date: 8/14/2018
Expiration Date: 4/8/2020

Target Audience:
The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients receiving immunotherapy.

Credit Designation:
This educational activity is designated for AMA PRA Category 1 Credit(s)™ for all physicians. All physicians will receive a CME Certificate and Canadian specialists can enter this activity as Section 2 personal learning in the Mainport of the Royal College of Physicians and Surgeons of Canada.

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The introduction of immune checkpoint inhibitors has had a great impact on the field of oncology. However, these new therapies are associated with a spectrum of autoimmune and systemic inflammatory reactions known as immune-related adverse events (irAEs). Rheumatologists are likely to encounter a wide variety of irAEs as the use of immune checkpoint inhibitors expands in the treatment of several cancers. Thus, it is critical for rheumatologists to be aware of these complications to accurately diagnose and manage the toxicities of immune checkpoint inhibitors in collaboration with treating oncologists. In this CME activity, expert faculty will review the role of the immune system in tumor biology and the appropriate management of rheumatic irAEs associated with immune checkpoint inhibitors. Case-based example will illustrate best practices for recognizing and managing these adverse events.

Learning Objectives:
Upon successful completion of this activity, participants should be better able to:
• Evaluate the mechanisms of action of immune checkpoint inhibitors as they relate to both their anti-tumoral response and their potential for autoimmunity.
• Review common irAEs and the role of immunosuppression in management and prevention.
• Assess multidisciplinary strategies for the optimal management of patients undergoing treatment with immune checkpoint inhibitor(s).

Intended Audience

Rheumatology, Oncology, Immunotherapies

Activity Payment Details

Activity Fee : NA

Rate this CME (Min 1 - Max 5)

Fee and expenses:
CME credits:
Program contents:
Write Your Review

Reviews Given by Professionals

No Reviews available. Be the first to write a review.

Privacy Policy

Read eMedEvents Privacy Policy


Vindico Medical Education

View Organizer Details